Abstract: The present invention provides variable reflectance automobile mirrors wherein the component of variable transmittance is an electrochromic device wherein the medium of variable transmittance comprises an electrochromic compound in a gel or a thickened solution.

Abstract: Isolated polynucleotide molecules and peptides encoded by these molecules can be used in the analysis of alloantigen phenotypes, as well as in diagnostic and therapeutic applications, relating to human platelet Pen polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from platelet mRNA, it is possible to type glycoprotein GPIIIa with regard to the Pen polymorphism, for example, in the context of diagnosing and treating clinical syndromes associated with GPIIIa-related immune responses.

Abstract: The present invention provides electrochromic layers, which comprise polymeric matrices with electrochromic solutions interspersed therein. Varying an electrical potential difference across a layer of the invention results in reversible variation in the transmittance of light across the layer because of electrochemical processes in the electrochromic solution of the layer. The invention further provides electrochromic devices, in which the electrochromic layers of the invention provide reversibly variable transmittance to light, and various apparatus in which the devices of the invention provide light-filtering or light-color modulation. Such apparatus include windows, including those for use inside and on the outside walls of buildings and in sunroofs for automobiles, and variable reflectance mirrors, especially rearview mirrors for automobiles.

Abstract: Methods and compositions are provided for hardening with fast-acting hardeners the colloidal carrier materials, such as gelatin, in the layers of photographic materials, such as photographic film. The methods of the invention comprise coating, with a conventional coating technique, among the layers of a photographic material a layer of a composition of the invention. The compositions of the invention are aqueous solutions which comprise a fast-acting hardener and a polymeric thickener, have concentrations of thickener less than about 50 mg/cm.sup.3 and, at 40.degree. C. and shear rates between about 1000 sec.sup.-1 and 10,000 sec.sup.-1, have viscosities from about 5 cp to about 20 cp and power law indices greater than about 0.90.

Abstract: Chimeric plasmids capable of transforming bacteria and yeast are described. The plasmids carry the Cm (chloramphenicol resistance) gene and the Tc (tetracycline resistance) gene as selectable markers. The Cm gene allows the plasmids to be selected for in wild-type strains of the yeast Saccharomyces cerevisiae. The Tc gene allows heterologous genes cloned into the plasmids to be selected for in Escherichia coli bacteria.

Abstract: The present invention provides novel 5-hydroxyfurochromones, which are useful as antiatherosclerotic agents.

Abstract: The present invention provides novel 7-methyl-6-methylthiomethylsulfinyl-, and methylsulfonylmethylfurochromones, which are useful as antiatherosclerotic agents.

Abstract: The present invention provides novel halofurochromones, which are useful as antiatherosclerotic agents.

Abstract: The administration of 25-hydroxycholecalciferol, 24,25-dihydroxycholecalciferol, 25,26-dihydroxycholecalciferol, 1,25-dihydroxycholecalciferol, 25-hydroxydihydrotachysterol.sub.3, 25-hydroxyergocalciferol, 1-.alpha.-hydroxycholecalciferol, and their acylates to hens increases the thickness of the egg shells. Compositions and methods are provided.

Abstract: The present specification describes a medicated device adapted for a single and rate-controlled rectal or vaginal administration to a mammal of a systemically active pharmaceutical (SAP). The device accomplishes drug administration at an essentially time-independent rate of dosage. Further, the device advantageously results in the substantial exhaustion of the SAP from the device at the conclusion of the single, acute use. The device comprises three elements:(A) an inert resilient support means contoured for easy vaginal or rectal insertion;(B) a first flexible polymer film layer affixed to the support means and containing the SAP dispersed therethrough, this first polymer film not being rate limiting as to the release of drug from the device; and(C) a second polymer film, laminated onto the first polymer film and providing a release rate therefrom of prostaglandin, which is rate limiting both as to the release of prostaglandin from the device and absorption rate by the rectal or vaginal tissues.

Abstract: The present invention provides novel benzo[1,2-b:5,4-b']difuran-3(2H)-ones, which are useful as antiatherosclerotic agents.